| Keosauqua Health Care Center | |
| 819 Country Lane Road, Keosauqua, Iowa 52565 | |
| (319) 293-3761 | |
| Name | Keosauqua Health Care Center |
|---|---|
| Location | 819 Country Lane Road, Keosauqua, Iowa |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 87.83% |
| Medicare ID (CCN) | 165204 |
| Legal Business Name | Keosauqua Health Care Center Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1013344191 |
| Organization Name | AEGIS |
| Address | 819 Country Lane Rd, Keosauqua, IA 52565 |
| Phone Number | 310-293-3671 |
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
| NPI Number | 1295324275 |
| Organization Name | OPCO KEOSAUQUA, IA, LLC |
| Doing Business As | KEOSAUQUA HEALTH CARE CENTER |
| Address | 819 Country Lane Rd, Keosauqua, IA 52565 |
| Phone Number | 319-293-3761 |
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
| NPI Number | 1821088485 |
| Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
| Doing Business As | GOOD SAMARITAN SOCIETY - VAN BUREN |
| Address | 819 Country Lane Rd, Keosauqua, IA 52565 |
| Phone Number | 319-293-3761 |
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
| NPI Number | 1982082418 |
| Organization Name | KEOSAUQUA HEALTH CARE CENTER LLC |
| Doing Business As | KEOSAUQUA HEALTH CARE CENTER |
| Address | 819 Country Lane Rd, Keosauqua, IA 52565 |
| Phone Number | 319-293-3761 |
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 22.16 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.03 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 36 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.29 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.89 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.6 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 7.73 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.48 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.61 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.22 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.7 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.42 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 23.08 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 2.44 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.07 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.77 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 92.19 | 82.93 |
News Archive
As three pharma majors, Pfizer Inc with partner BioNTech SE, Moderna Inc. and AstraZeneca Plc announced this month the effectiveness of their experimental vaccines in preventing COVID-19, there were no guarantees that developing countries will get their fair share.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.
› Verified 3 days ago
Keosauqua Health Care Center Location: 819 Country Lane Road, Keosauqua, Iowa 52565 Phone: (319) 293-3761 |